Biosino Bio-Technology and Science Incorporation Balance Sheet Health
Financial Health criteria checks 5/6
Biosino Bio-Technology and Science Incorporation has a total shareholder equity of CN¥231.4M and total debt of CN¥142.7M, which brings its debt-to-equity ratio to 61.7%. Its total assets and total liabilities are CN¥563.3M and CN¥331.8M respectively.
Key information
61.7%
Debt to equity ratio
CN¥142.72m
Debt
Interest coverage ratio | n/a |
Cash | CN¥72.09m |
Equity | CN¥231.40m |
Total liabilities | CN¥331.85m |
Total assets | CN¥563.25m |
Recent financial health updates
Recent updates
Biosino Bio-Technology and Science Incorporation (HKG:8247) Held Back By Insufficient Growth Even After Shares Climb 46%
Apr 22Is Biosino Bio-Technology and Science Incorporation (HKG:8247) Using Debt In A Risky Way?
Apr 01Biosino Bio-Technology and Science Incorporation's (HKG:8247) 31% Dip In Price Shows Sentiment Is Matching Revenues
Feb 08Some Confidence Is Lacking In Biosino Bio-Technology and Science Incorporation (HKG:8247) As Shares Slide 38%
Jul 31We Think That There Are Issues Underlying Biosino Bio-Technology and Science Incorporation's (HKG:8247) Earnings
Aug 19Financial Position Analysis
Short Term Liabilities: 8247's short term assets (CN¥350.1M) exceed its short term liabilities (CN¥320.7M).
Long Term Liabilities: 8247's short term assets (CN¥350.1M) exceed its long term liabilities (CN¥11.1M).
Debt to Equity History and Analysis
Debt Level: 8247's net debt to equity ratio (30.5%) is considered satisfactory.
Reducing Debt: 8247's debt to equity ratio has increased from 54.1% to 61.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 8247 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 8247 has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 58.4% each year.